NU215-01, mesenchymal stem cells for treatment of systemic lupus erythematosus
The aim of this study was to determine the safety and efficacy of treatment of systemic lupus erythematosus (SLE) with allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs). The findings indicate that UC-MSC transplantation results in amelioration of disease activity, serologic changes, and stabilization of proinflammatory cytokines.
Read More
Product Information for
NU215-01, mesenchymal stem cells for treatment of systemic lupus erythematosus
Links related to the product - may include a range of information sources (e.g., press releases, websites, patents) related to the specific cell therapy application.
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access